Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LIMN

Liminatus Pharma Inc

Feb 06 • 04:00PM ET

1.84

-0.21 -10.24 %

Healthcare • Biotechnology • USA • NASD

Feb 05, 10:01 AMNasdaq compliance restoration announcement sparked multi-day rally culminating in today's 22.50% gain.

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	79.47%	Shs Outstand	27.06M	Perf Week	234.42%
Market Cap	49.80M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.56M	Perf Month	95.83%
Enterprise Value	50.52M	PEG	-	EPS next Q	-	Inst Own	0.89%	Short Float	1.22%	Perf Quarter	40.46%
Income	-2.58M	P/S	-	EPS this Y	-	Inst Trans	9.23%	Short Ratio	0.01	Perf Half Y	-61.90%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-116.93%	Short Interest	0.07M	Perf YTD	201.64%
Book/sh	-0.06	P/C	69.17	EPS next 5Y	-	ROE	-	52W High	33.66 -94.53%	Perf Year	-84.60%
Cash/sh	0.03	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	0.54 240.80%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	65.41% 23.30%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	46.82%	Oper. Margin	-	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.42	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	74.75	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.42	EPS Q/Q	24.67%	SMA20	108.97%	Beta	-0.34	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	119.29%	Rel Volume	9.89	Prev Close	2.05
Employees	3	LT Debt/Eq	-	Earnings	-	SMA200	-57.49%	Avg Volume	4.55M	Price	1.84
IPO	May 26, 2021	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	44,962,850	Change	-10.24%

Oct-30-25 10:04AM	Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation (GlobeNewswire)
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +22.66%
Aug-05-25 12:11PM	BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism (CoinDesk)
Jul-28-25 07:30AM	Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative (GlobeNewswire) -7.23%
Jul-25-25 08:31AM	Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies (GlobeNewswire)
08:31AM	Loading…
Jul-24-25 08:31AM	Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy (GlobeNewswire) +30.91%
Jul-22-25 01:30PM	Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy (GlobeNewswire)

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIMN

Liminatus Pharma Inc

Upgrade your FINVIZ experience